GI
PTGX icon

GAMMA Investing’s Protagonist Therapeutics PTGX Stock Holding History

GAMMA Investing’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$496K Buy
3,518
+409
+13% +$58.3K 0.02% 703
2026
Q2 		$381K Buy
3,109
+208
+7% +$21.7K 0.01% 805
2026
Q1 		$306K Buy
2,901
+229
+9% +$20.3K 0.01% 834
2025
Q4 		$233K Buy
2,672
+1,024
+62% +$83.8K 0.01% 928
2025
Q3 		$109K Buy
1,648
+571
+53% +$32.5K 0.01% 1434
2025
Q2 		$59.5K Sell
1,077
-126
-10% -$6.05K ﹤0.01% 1818
2025
Q1 		$58.2K Buy
1,203
+728
+153% +$30.5K ﹤0.01% 1689
2024
Q4 		$18.3K Sell
475
-77
-14% -$3.36K ﹤0.01% 2306
2024
Q3 		$24.8K Buy
552
+487
+749% +$19.7K ﹤0.01% 1971
2024
Q2 		$2.25K Buy
65
+17
+35% +$498 ﹤0.01% 2846
2024
Q1 		$1.39K Buy
48
+23
+92% +$626 ﹤0.01% 2867
2023
Q4 		$625 Buy
+25
New +$437 ﹤0.01% 2911

Other funds holding PTGX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's PTGX Position: Q3 2026 in Review

GAMMA Investing increased its Protagonist Therapeutics (PTGX) stake by 13% in Q3 2026, buying an estimated $58.3K and bringing the position to 3,518 shares worth $496K. The position accounts for 0.02% of the portfolio, ranked #703.

GAMMA Investing first reported a position in PTGX in Q4 2023 and has held it in 12 quarters since. 10 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • GAMMA Investing held 3,518 shares of Protagonist Therapeutics worth $496K as of Q3 2026.
  • GAMMA Investing bought 409 Protagonist Therapeutics shares in Q3 2026, an estimated $58.3K.
  • Protagonist Therapeutics made up 0.02% of GAMMA Investing's portfolio in Q3 2026, its #703 holding.
  • GAMMA Investing first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 10 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.